Affiliation:
1. Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University
2. Key Laboratory for Zoonosis Research, Ministry of Education, College of Veterinary Medicine, Jilin University
Abstract
Leptospirosis is an emerging infectious disease caused by pathogenic
Leptospira
spp. Humans and some mammals can develop severe forms of leptospirosis accompanied by a dysregulated inflammatory response, which often results in death. The gut microbiota has been increasingly recognized as a vital element in systemic health. However, the precise role of the gut microbiota in severe leptospirosis is still unknown. Here, we aimed to explore the function and potential mechanisms of the gut microbiota in a hamster model of severe leptospirosis. Our study showed that leptospires were able to multiply in the intestine, cause pathological injury, and induce intestinal and systemic inflammatory responses. 16S rRNA gene sequencing analysis revealed that
Leptospira
infection changed the composition of the gut microbiota of hamsters with an expansion of Proteobacteria. In addition, gut barrier permeability was increased after infection, as reflected by a decrease in the expression of tight junctions. Translocated Proteobacteria were found in the intestinal epithelium of moribund hamsters, as determined by fluorescence in situ hybridization, with elevated LPS levels in the serum. Moreover, gut microbiota depletion reduced the survival time, increased the leptospiral load, and promoted the expression of proinflammatory cytokines after
Leptospira
infection. Intriguingly, fecal filtration and serum from moribund hamsters both increased the transcription of
TNF-α
,
IL-1β
,
IL-10
, and
TLR4
in macrophages compared with those from uninfected hamsters. These stimulating activities were inhibited by LPS neutralization using polymyxin B. Based on our findings, we identified an LPS neutralization therapy that significantly improved the survival rates in severe leptospirosis when used in combination with antibiotic therapy or polyclonal antibody therapy. In conclusion, our study not only uncovers the role of the gut microbiota in severe leptospirosis but also provides a therapeutic strategy for severe leptospirosis.
Publisher
eLife Sciences Publications, Ltd
Reference59 articles.
1. Pathogenesis insights from an ancient and ubiquitous spirochete;PLoS Pathog,2021
2. Leptospirosis in humans;Curr Top Microbiol Immunol,2015
3. Challenges for the development of a universal vaccine against leptospirosis revealed by the evaluation of 22 vaccine candidates;Front Cell Infect Microbiol,2022
4. Kinetics of
Leptospira interrogans
infection in hamsters after intradermal and subcutaneous challenge;PLoS Negl Trop Dis,2014
5. The Jarisch-Herxheimer reaction in leptospirosis: a systematic review;PLoS One,2013